Header Logo

Connection

JEFFREY E GERSHENWALD to Risk Assessment

Back to Details
This is a "connection" page, showing publications JEFFREY E GERSHENWALD has written about Risk Assessment.
JEFFREY E GERSHENWALD
Connection Strength
0.582
Risk Assessment
  1. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018 08; 18(8):775-784.
    View in: PubMed
    Score: 0.261
  2. Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. J Natl Cancer Inst. 2020 09 01; 112(9):875-885.
    View in: PubMed
    Score: 0.075
  3. Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. J Invest Dermatol. 2017 08; 137(8):1792-1795.
    View in: PubMed
    Score: 0.060
  4. Management of early-stage cutaneous melanoma. Curr Probl Surg. 2005 Jul; 42(7):460-534.
    View in: PubMed
    Score: 0.026
  5. Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark. Eur J Surg Oncol. 2005 Apr; 31(3):323-4.
    View in: PubMed
    Score: 0.026
  6. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol. 2020 05 01; 38(13):1429-1441.
    View in: PubMed
    Score: 0.018
  7. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020 03; 33(3):496-513.
    View in: PubMed
    Score: 0.017
  8. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
    View in: PubMed
    Score: 0.016
  9. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
    View in: PubMed
    Score: 0.016
  10. Critical Assessment of Clinical Prognostic Tools in Melanoma. Ann Surg Oncol. 2016 09; 23(9):2753-61.
    View in: PubMed
    Score: 0.014
  11. Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. J Invest Dermatol. 2015 Sep; 135(9):2266-2272.
    View in: PubMed
    Score: 0.013
  12. A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. J Am Coll Surg. 2012 Apr; 214(4):608-17; discussion 617-9.
    View in: PubMed
    Score: 0.010
  13. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010 May 10; 28(14):2452-9.
    View in: PubMed
    Score: 0.009
  14. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer. 2008 May 01; 122(9):2077-84.
    View in: PubMed
    Score: 0.008
  15. In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. J Natl Cancer Inst. 2005 Dec 21; 97(24):1822-31.
    View in: PubMed
    Score: 0.007
  16. Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst. 2003 Feb 19; 95(4):308-15.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.